

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

VOLUNTARY ANNOUNCEMENT

MemoSorb® BIODEGRADABLE ATRIAL SEPTAL DEFECT OCCLUDER PRODUCT OBTAINS MEDICAL DEVICE REGISTRATION CERTIFICATE

The board of directors (the “**Board**”) of LPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) is pleased to announce that Shanghai Shape Memory Alloy Co., Ltd.# (上海形狀記憶合金材料有限公司), a wholly-owned subsidiary of the Company, has obtained a medical device registration certificate granted by the National Medical Products Administration of the People's Republic of China for the MemoSorb® Biodegradable Atrial Septal Defect Occluder Product (“**MemoSorb® Biodegradable ASD Occluder Product**”).

MemoSorb® Biodegradable ASD Occluder Product is innovatively designed to meet the needs of atrial septal defect occluder, breaking through many limitations of current metal occluders. In particular, compared with nickel-titanium alloys, biodegradable polydioxanone materials have better biocompatibility that significantly reduce inflammatory reactions, alleviate fibrosis, and promote endothelialization. Moreover, the interatrial septum is reconstructed after the occluder is degraded. Tissue elasticity is retained and does not affect the subsequent transseptal interventional treatment path, which is more conducive to the long-term health benefits of the patient. The approval for commercialization of the MemoSorb® Biodegradable ASD Occluder Product has enriched the Company's biodegradable product line. It is expected to further open up market opportunities both domestically and internationally in the field of congenital heart disease medical devices, thereby providing better options and experiences for patients with congenital heart disease.

In future, the Company will unswervingly be at the forefront of innovation, closely focusing on the actual clinical needs, delve into the field of structural heart disease, develop more high-quality, high-performance products, to contribute safer and more efficient medical products for the patients in China and around the world, and to promote the prosperous development of the global healthcare industry.

The sales performance of MemoSorb® Biodegradable ASD Occluder Product will be subject to a number of factors including but not limited to clinical promotion, channel expansion, changes in competitive landscape and macro policies, in which there exist uncertainties of this product on the Company's financial performance.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
August 15, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*

For identification purposes only.